clinical_frontiers revision_clean 050923

399

10

Acknowledgments

400

A preprint of this manuscript has been published online at medRxiv.

401

11

Data Availability Statement

The data that support the findings of this study are openly available in SRA at 402 https://www.ncbi.nlm.nih.gov/bioproject/PRJNA922968, reference number PRJNA922968. 403

404

405

406

407

408

409

410

411

412

413

414

415

References

416

1. Bowerman KL, Rehman SF, Vaughan A, Lachner N, Budden KF, Kim RY, et al. Disease- 417 associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary 418 disease. Nat Commun. 2020;11(1):5886. 419 2. Yeoh YK, Zuo T, Lui GC-Y, Zhang F, Liu Q, Li AY, et al. Gut microbiota composition 420 reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 421 2021;70(4):698-706. 422 3. Yazar A, Atis S, Konca K, Pata C, Akbay E, Calikoglu M, et al. Respiratory symptoms and 423 pulmonary functional changes in patients with irritable bowel syndrome. Am J Gastroenterol. 424 2001;96(5):1511-6. 425 4. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, et al. Disordered microbial 426 communities in asthmatic airways. PLoS One. 2010;5(1):e8578. 427 5. Marri PR, Stern DA, Wright AL, Billheimer D, Martinez FD. Asthma-associated differences 428 in microbial composition of induced sputum. J Allergy Clin Immunol. 2013;131(2):346-52 e1-3. 429

15

Powered by